The most common side effects of cholesterol injections are injection-site reactions and flu-like symptoms, followed by muscle and joint aches. These injectable medications, known as PCSK9 inhibitors (alirocumab and evolocumab) and the newer siRNA therapy inclisiran, are prescribed when statins alone are not enough or not tolerated, and their overall safety profile in clinical trials has been reassuring. But real-world experience has revealed a broader picture that is worth understanding before you start treatment or switch from one drug to another.
What Counts as a Cholesterol Injection
When people say “cholesterol injection” or “cholesterol shot,” they are almost always talking about one of three drugs. Alirocumab (Praluent) and evolocumab (Repatha) are monoclonal antibodies that block a protein called PCSK9, which normally tells your liver to recycle its LDL receptors. By blocking that signal, these drugs let your liver pull more LDL cholesterol out of the blood. You inject them under the skin every two or four weeks, depending on the drug and dose. The third option, inclisiran (Leqvio), works upstream by silencing the gene that makes PCSK9 in the first place, so your liver produces less of the protein. Inclisiran is given just twice a year after an initial pair of doses. All three are subcutaneous injections, meaning the needle goes into the fatty tissue just beneath the skin of your thigh, abdomen, or upper arm.
Injection-Site Reactions Are the Most Frequent Complaint
Soreness, redness, bruising, or swelling at the spot where the needle went in is far and away the most commonly reported problem. In a hospital registry tracking real-world patients on PCSK9 inhibitors, about a third reported injection-site reactions, making it the single most frequent adverse event in that group. FDA adverse-event reports echo the pattern: injection-site pain, bruising, bleeding, and redness were the most commonly flagged issues for both alirocumab and evolocumab.
For most people, these reactions are mild and fade within a day or two. Letting the prefilled syringe or pen warm to room temperature before injecting, rotating injection sites, and avoiding areas with bruises or scars can help. Occasionally, though, the reaction is more persistent. One documented case involved a young woman with familial hypercholesterolemia who developed a painful, palpable lump 48 hours after her second alirocumab injection. The reaction came back after her third dose. When she was switched to evolocumab, the same type of reaction appeared again. Investigators suspected a cell-mediated hypersensitivity reaction to polysorbate, an inactive ingredient found in both drugs. She was ultimately switched to inclisiran, which does not contain that excipient, and did well on it.
Flu-Like Illness and Musculoskeletal Aches
After injection-site issues, the next tier of side effects involves symptoms that feel systemic: low-grade fever, sore throat, runny nose, chills, and general achiness. In the same real-world registry, roughly 28% of patients reported flu-like illness. Upper respiratory symptoms such as nasopharyngitis and sinus congestion are listed as common side effects in the European prescribing information for evolocumab.
Muscle and joint pain also show up regularly. Post-marketing surveillance data from the European adverse-event database (EudraVigilance) found that musculoskeletal complaints, including myalgia, back pain, and joint pain, were among the most frequently reported serious suspected adverse reactions for evolocumab. In global pharmacovigilance databases, myalgia was the single most common adverse event reported for PCSK9 inhibitors overall.
This is an especially sore point (literally) for the people who end up on these injections in the first place. Many are prescribed a PCSK9 inhibitor precisely because they could not tolerate statin-related muscle pain. So when muscle symptoms show up again on the new medication, it is understandably frustrating. The evidence suggests that muscle complaints with PCSK9 inhibitors are less frequent and less severe than with high-dose statins, but they are not zero. If muscle pain was your reason for leaving statins behind, it is worth keeping a symptom diary during the first few months on the injection so you and your doctor can tell whether the new treatment is genuinely the culprit or whether something else is going on.
Headache, Nausea, and Other Common Nuisances
Headache appears consistently across both clinical-trial data and real-world adverse-event reports for alirocumab and evolocumab. Nausea and diarrhea round out the list of gastrointestinal complaints seen in post-marketing data for evolocumab, with diarrhea among the more frequently reported serious events in the EudraVigilance analysis. These side effects are rarely severe enough to stop treatment, but they can be annoying, especially in the first few months.
Rare but Serious Allergic Reactions
Urticaria (hives) and angioedema (swelling beneath the skin, sometimes around the face or throat) appear as infrequent but serious adverse reactions in the post-marketing surveillance of evolocumab. A case report in a cardiology journal described a life-threatening reaction to a PCSK9 monoclonal antibody, though such events are exceedingly rare. Because alirocumab and evolocumab are “fully human” monoclonal antibodies, meaning they are engineered to resemble natural human antibodies closely, they have low immunogenicity. In the large FOURIER trial of evolocumab, only about 0.3% of patients developed new binding antibodies to the drug, and those antibodies did not interfere with the drug’s effectiveness or safety. By contrast, bococizumab, an earlier PCSK9 inhibitor that retained a small percentage of mouse-derived sequences, generated enough anti-drug antibodies that its clinical trials were terminated early.
The practical takeaway: true allergic reactions to alirocumab or evolocumab are uncommon, but you should be aware of the signs, especially hives spreading beyond the injection site, facial swelling, or difficulty breathing. If the reaction seems linked to the polysorbate excipient rather than the antibody itself, switching to inclisiran may be an option, as the case described earlier illustrates.
Does Dropping LDL Very Low Cause Cognitive Problems?
This is one of the most common worries people have about cholesterol injections, and it is worth addressing head-on. PCSK9 inhibitors can drive LDL cholesterol down to levels rarely seen in nature, sometimes below 25 mg/dL. Because cholesterol is a component of brain cell membranes and myelin, the insulating sheath around nerve fibers, some patients and physicians worry that extremely low LDL could starve the brain of a nutrient it needs.
The FDA flagged this concern early on, and dedicated studies followed. In a cognitive sub-study of the FOURIER trial, patients on evolocumab performed essentially the same as those on placebo on standardized memory and executive-function tests over the course of the trial. Patients whose LDL dropped below 25 mg/dL scored comparably to those with higher levels. Reports of cognitive side effects from both patients and investigators were similar in the evolocumab and placebo groups.
A broader review of the evidence around intensive LDL-lowering (including both statins and PCSK9 inhibitors) concluded that the data remain mixed but do not support a clear link between low LDL and clinically meaningful cognitive decline. Some studies have even suggested a possible benefit in dementia prevention, though that evidence is preliminary. The bottom line from the current research is that very low LDL levels achieved by PCSK9 inhibitors do not appear to impair thinking or memory, but the question has not been fully closed, and longer follow-up studies are still accumulating data.
Hormones, Vitamin E, and Steroid Production
Cholesterol is a building block for steroid hormones like cortisol, testosterone, and estrogen, so it stands to reason that slashing blood cholesterol levels might interfere with the body’s ability to make those hormones. A dedicated analysis from the 52-week DESCARTES trial specifically looked at this concern. Among patients treated with evolocumab, gonadal hormones (testosterone and estrogen-related markers) did not change from baseline to the end of the year. Cortisol showed a slight uptick, but the adrenocorticotropic hormone level and the ratio between cortisol and that hormone stayed stable, meaning the adrenal glands were not being stressed. Vitamin E levels, which travel in the blood attached to LDL particles and could theoretically drop alongside LDL, were also assessed; no clinically meaningful changes emerged. These findings held even among patients whose LDL fell to very low levels.
This is reassuring because it tells us that the liver can still manufacture enough cholesterol locally for hormone production even when circulating LDL is drastically reduced. The cholesterol your body uses for hormones is produced inside cells, not pulled from the bloodstream, which helps explain why slashing blood LDL does not tank your hormone levels.
Hemorrhagic Stroke Risk
One longstanding concern with aggressive cholesterol lowering is a possible increase in hemorrhagic stroke, the type caused by bleeding in the brain rather than a clot. This worry comes mainly from the statin literature, where higher-dose statins have been associated with a modest increase in hemorrhagic stroke risk. A comparative meta-analysis specifically examined whether PCSK9 inhibitors carry the same signal. Statins across all doses showed a statistically significant increase in hemorrhagic stroke risk, and higher-dose statins magnified that risk further. PCSK9 inhibitors, by contrast, showed no increase whatsoever. In the analysis of higher-potency PCSK9 inhibitor use, which included over 27,000 patients, the hemorrhagic stroke signal was flat. A separate review from the American College of Cardiology confirmed that adding a PCSK9 inhibitor on top of maximally tolerated statins did not raise hemorrhagic stroke rates compared to statins alone, even in patients with a prior history of cerebral ischemia.
This is one area where the injectable cholesterol drugs actually look safer than the oral ones, at least based on the evidence available so far. If you have been told you are at elevated risk for hemorrhagic stroke, this data point may be part of why your doctor steered you toward a PCSK9 inhibitor rather than simply increasing your statin dose.
Cataracts and Eye Health
Because the lens of the eye contains cholesterol, there was theoretical concern that very low LDL levels might affect lens clarity and promote cataract formation. A large analysis of the ODYSSEY OUTCOMES trial, which followed nearly 19,000 patients with recent acute coronary syndromes, examined this directly. After a median follow-up of about 2.8 years, cataract rates were virtually identical in the alirocumab and placebo groups. Even among patients whose LDL dropped below 25 mg/dL on at least two occasions, or below 15 mg/dL, cataract rates were no higher than in matched placebo patients. Very low achieved LDL levels did not appear to increase cataract incidence.
The New-Onset Diabetes Question
Statins carry a well-established, modest increase in the risk of developing type 2 diabetes, particularly at higher doses. Whether PCSK9 inhibitors share this tendency is still being sorted out. The FOURIER open-label extension trial, which followed over 6,500 patients for a median of about five years, observed a slightly higher annualized incidence of new-onset diabetes among patients whose LDL fell below 20 mg/dL compared to those with LDL above 70 mg/dL. But the researchers flagged several important caveats: routine screening for diabetes was not part of the protocol, so milder cases may have been missed in both groups; fasting glucose and HbA1c were not collected systematically; and since all patients in the extension phase were on PCSK9 inhibitor therapy, there was no true control group against which to compare the signal. The finding was observational and could not be directly attributed to the drug itself.
For now, most guidelines do not list new-onset diabetes as a confirmed side effect of PCSK9 inhibitors, but if you have prediabetes or strong risk factors for type 2 diabetes, your doctor may want to keep a closer eye on your blood sugar after starting treatment. This is one of those areas where the evidence is thin enough that the honest answer is “we don’t know yet for sure.”
How Often People Stop Treatment Because of Side Effects
Clinical trials are carefully controlled environments, and people who agree to join them tend to be more motivated to stick with a medication than the general population. Real-world data paint a somewhat different picture of tolerability. In one hospital registry, about 7% of patients discontinued their PCSK9 inhibitor, almost all because of side effects. Most of those who stopped were women, and a large portion reported three or more adverse events before quitting. In a separate Dutch pharmacovigilance database, the discontinuation rate was substantially higher, with 40% of patients who submitted adverse-event reports stopping treatment. That figure is likely skewed upward because the database captures reports from people who are already having problems, but it suggests that the burden of side effects is heavier in routine clinical practice than trial results imply.
Cost and insurance hassles also play a role in real-world adherence that has nothing to do with side effects, so these numbers reflect a messy mix of factors. Still, if you are struggling with recurring side effects, you are not alone, and it is worth talking to your doctor about switching between alirocumab and evolocumab, trying inclisiran, or adjusting your injection technique before giving up on the class entirely.
How Inclisiran Compares
Inclisiran works by a fundamentally different mechanism than the monoclonal antibodies. Instead of blocking the PCSK9 protein in the bloodstream, it silences the gene inside liver cells so the protein is never made in the first place. Because it is a small-interfering RNA rather than a large antibody molecule, and because it is dosed only twice a year after the loading phase, its side-effect profile has some differences. Clinical evaluation of inclisiran at the 300 mg dose found it to be well tolerated with no specific safety concerns identified. Injection-site reactions still occur, since the drug is given subcutaneously, but the sheer infrequency of dosing means you deal with them far less often. The case report described earlier, where a patient who reacted to both alirocumab and evolocumab tolerated inclisiran without issues, also suggests that the excipient-related allergic reactions seen with the monoclonal antibodies may not carry over.
Inclisiran is newer, however, which means there is less long-term safety data. The large cardiovascular-outcome trials for inclisiran are still ongoing or recently completed, so we do not yet have the depth of extended follow-up that exists for evolocumab and alirocumab. If you are choosing between these drugs, your doctor will weigh the convenience of twice-yearly dosing against the longer track record of the older options.
What the Skin Reactions Actually Look Like
Post-marketing surveillance for evolocumab identified skin reactions as a distinct category beyond injection-site complaints. These include rash, urticaria, and occasionally eczema or dermatitis that is not confined to the injection area. In the EudraVigilance data, skin-related adverse events showed up alongside musculoskeletal complaints, flu-like symptoms, and metabolic disturbances as part of the broader real-world side-effect landscape. If you develop a rash that appears days after your injection and spreads to areas far from the injection site, that warrants a call to your prescribing clinician, both to document it and to decide whether the medication is the likely cause or whether something unrelated is going on.
Metabolism and Nutrition Concerns in Post-Marketing Data
The EudraVigilance analysis of evolocumab flagged metabolism and nutrition disorders as a category that appeared in both pre-authorization trials and post-marketing surveillance. This broad bucket can include changes in appetite, alterations in blood sugar (overlapping with the diabetes question discussed above), and electrolyte shifts. None of these were frequent enough to change prescribing recommendations, but they are tracked as part of ongoing pharmacovigilance. If you notice unusual changes in appetite, energy, or weight after starting a PCSK9 inhibitor, mention them at your next visit so they can be documented and evaluated in context.